PT  - JOURNAL ARTICLE
AU  - NAN-YUNG HSU
AU  - HWEI-CHUNG WANG
AU  - CHUNG-HSING WANG
AU  - CHANG-FANG CHIU
AU  - HSIEN-CHANG TSENG
AU  - SHIU-YUN LIANG
AU  - CHIA-WEN TSAI
AU  - CHENG-CHIEH LIN
AU  - DA-TIAN BAU
TI  - Lung Cancer Susceptibility and Genetic Polymorphisms of <em>Exo1</em> Gene in Taiwan
DP  - 2009 Feb 01
TA  - Anticancer Research
PG  - 725--730
VI  - 29
IP  - 2
4099  - http://ar.iiarjournals.org/content/29/2/725.short
4100  - http://ar.iiarjournals.org/content/29/2/725.full
SO  - Anticancer Res2009 Feb 01; 29
AB  - Aim: To evaluate the association between the polymorphisms of the Exo1 gene and the risk of lung cancer in central Taiwan. Patients and Methods: In this hospital-based study, the association of Exo1 A-1419G (rs3754093), C-908G (rs10802996), A238G (rs1776177), C498T (rs1635517), K589E (rs1047840), G670E (rs1776148), C723R (rs1635498), L757P (rs9350) and C3114T (rs851797) polymorphisms with lung cancer risk in a central Taiwanese population was investigated. In total, 358 patients with lung cancer and 358 age- and gender-matched healthy controls recruited from the China Medical Hospital in central Taiwan were genotyped. Results: A significantly different distribution was found in the frequency of the Exo1 K589E genotype, but not the other genotypes, between the lung cancer and control groups. The A allele Exo1 K589E conferred a significantly (p=0.0097) increased risk of lung cancer. As for the rest of the polymorphisms, there was no difference in distribution between the lung cancer and control groups. Gene environment interactions with smoking were significant for Exo1 K589E polymorphism. The Exo1 K589E AG and AA genotype in association with smoking conferred an increased risk of 1.7208 (95% confidence interval=1.2188-2.4295) for lung cancer. Conclusion: Our results provide the first evidence that the A allele of Exo1 K589E may be associated with the development of lung cancer and may be a novel useful marker for primary prevention and anticancer intervention. Copyright© 2009 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved